MétaCan
Menu
Back to cohort
Record W3176099878 · doi:10.1002/hon.49_2879

IMPACT OF DIFFERENT INDUCTION REGIMENS ON THE OUTCOME OF PRIMARY MEDIASTINAL B CELL LYMPHOMA IN THE PROSPECTIVE IELSG 37 TRIAL

2021· article· en· W3176099878 on OpenAlexaff
Maurizio Martelli, Emanuele Zucca, Barbara Botto, Irina Kryachok, Luca Ceriani, Monica Balzarotti, Alessandra Tucci, M. G. Cabras, Vittorio Ruggero Zilioli, C. Rusconi, F. Angrilli, Luca Arcaini, A. Dabrowska Iwanicka, Andrés J.M. Ferreri, Francesco Merli, Weili Zhao, David Hodgson, C Ionescu, Alexander Fosså, Kate Cwynarski, G. Mikhaeel, Mats Jerkeman, Andrea Janíková, Andreas Hüttmann, Giovannino Ciccone, Ur Metser, Sally F. Barrington, Bogdan Małkowski, Annibale Versari, F. Espósito, Kelly Cozens, Nicoletta Ielmini, R. Ricardi, Franco Cavalli, Peter Johnson, Alex Davies

Bibliographic record

VenueHematological Oncology · 2021
Typearticle
Languageen
FieldMedicine
TopicLymphoma Diagnosis and Treatment
Canadian institutionsPrincess Margaret Cancer CentreSt. Thomas HospitalUniversity Health Network
FundersPharmacyclicsSwiss Cancer Research FoundationSchweizerische Arbeitsgemeinschaft für Klinische KrebsforschungSchweizerischer Nationalfonds zur Förderung der Wissenschaftlichen ForschungCelltrionBeiGeneAstraZenecaCelltrion HealthcareGilead SciencesCelgeneAmgenPfizerCancer Research UKIncyteNational Science Foundation
KeywordsMedicineClinical endpointRegimenRituximabChemoimmunotherapyInternal medicineOncologyPopulationRandomized controlled trialLymphomaSurgery

Abstract

fetched live from OpenAlex

Introduction: Primary mediastinal B-cell lymphoma (PMBCL) is characterized by poor prognosis if adequate responses are not rapidly achieved or if the disease recurs. Therefore, dose-intensive chemoimmunotherapy regimens are widely used but their superiority over the standard R-CHOP21 regimen has not been proven by randomized trials, furthermore they come with significant associated toxicities. Radiotherapy (RT) can consolidate responses after induction, but it may increase the risk of second malignancies and accelerate coronary heart disease. The IELSG37 trial was planned according to a non-inferiority design to demonstrate that RT may be unnecessary in patients achieving a metabolic complete remission. The primary-endpoint analysis per arm will be reported when >80% will have a minimum post-treatment follow-up of 30 months. Herein we present a preliminary analysis of the outcomes after different induction regimens in the whole study population. Methods: Patients with newly diagnosed PMBCL were eligible. Initial therapy was to be based on a combination containing rituximab and anthracyclines. The regimen was chosen according to local practice. Upon central review of post-induction PET scans, responding patients were randomized to observation versus consolidative RT. Responses were defined according to the Lugano classification using the Deauville 5-point scale (DS). Patients progressing during induction did not have central PET review and in the present analysis were assigned DS score 5. Results: 545 patients (209 men, 336 women) were enrolled and treated with R-V/MACOP-B (n = 168, 31%), R-CHOP14 (n = 146, 27%), R-CHOP21 (n = 98, 18%), DA-EPOCH-R (n = 88, 16%), R-megaCHOP (n = 19, 3%), other dose-intensive regimen (n = 26, 5%). At a median follow up of 3 years, approx. 95% of patients are alive. The rate of complete metabolic responses (CR, defined by DS 1-3) did not differ significantly across regimens, however an unbalanced distribution of DS score was evident, apparently due to the rate of patients with a probable induction failure (DS5) more than 2 times higher for CHOP21 in comparison to the other regimens. At preliminary univariate analysis there was no significant association of advanced stage, older age, extranodal infiltration, poor performance status, bulky disease, unfavorable international prognostic index (IPI) and larger metabolic tumor volume (MTV) with the use of CHOP21. Patients receiving DA-EPOCH-R were somehow younger than the rest. The research was funded by: IELSG37 was supported in part by grants from Swiss National Science Foundation (SNSF) – Project 32003B_146931,Krebsforschung Schweiz – Projec KFS-2852-08-2011 and Cancer Research UK (C30423/A16247)The enrolment of Swiss patients was supported by the Swiss Group for Clinical Cancer Research (SAKK) Keywords: Chemotherapy Combination, Therapies Immunotherapy No conflicts of interests pertinent to the abstract.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.035
Threshold uncertainty score0.273

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.072
GPT teacher head0.352
Teacher spread0.280 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations13
Published2021
Admission routes1
Has abstractyes

Explore more

Same venueHematological OncologySame topicLymphoma Diagnosis and TreatmentFrench-language works237,207